熊去氧胆酸胶囊在治疗胆汁淤积性肝病中的免疫调节作用  

作　　者：马振华[1] 孙成学[1] 都大林 石宏[1] 

机构地区：[1]北华大学附属医院感染肝病科,吉林吉林132011

出　　处：《检验医学》2016年第B11期298-299,共2页Laboratory Medicine

基　　金：吉林市科技局项目（201339016）.

摘　　要：目的观察熊去氧胆酸胶囊治疗的胆汁淤积性耵：病患者，肝脏生化指标和细胞网子治疗后的变化特点。方法将50例胆汁淤积性肝病患者随机分为治疗组（30例）和对照组（20例），治疗组患者在对照组治疗鹱础上加服熊去氧胆酸胶囊0．25g／次，每日三次，两组患者均治疗1个月。分别于治疗前后检测患者肝功能、血清肿瘤坏死因子-α（TNF-α）、内细胞介素4（IL-4）、白细胞介素-6（IL-6）和于扰索-γ（IFN-γ）。结果治疗前，两组患者mL清ALT、AST、TBiL、DBiL、7-GGT、ALP、TNF-α、IL-4、IL-6、IFN～y水平比较，差异无统计学意义（P〉0．05）；治疗后，治疗组患者血清ALT、AST、TBiL、DBiL、7-GGT、ALL、TNF-α、IFN7与治疗前相比较前下降，IL-4、IL-6水平较前升高，差异均有统计学意义（P〈0．05），Th1烈细胞因子水平下降，Th2型细胞因子水平升高；治疗后，与对照组治疗后比较，治疗组IL-4、IL-6水平升高，TNF-α、IFN-γ水平下降，差异有统计学意义（P〈0．05）。结论熊去氧胆酸胶囊治疗淤胴删肝病的作用机制可能与抑制Th1型细胞因子TNF-α和IFN-γ的释放，及刺激Th2型细胞因子IL-4和IL-6的释放有关。熊去氧腱酸胶囊对腿汁淤积性肝病患者有-定的免疫调节作用。Abstract： Objective To investigate the characteristics of liver function and cytokines in patients with cholestasis and their changes after therapy. Methods 50 cases of patients with cholestasia liver disease were randomly divided into control group and treatment group, 20 cases in control group and 30 eases in treatment group. On the basis of therapy method of control group,Treatment group patients add Ursodeoxycholic Acid capsules 0.25 g/time, three times a day, two groups were treated for one months. Liver function, serum interleukin 4 （IL-4）, interleukin 6 （IL-6）, interferon gamma （IFN gamma） and tumor necrosis factor alpha （TNF-α） lev- els were detected in two groups before and after treatment respectively. Results Before the treatment, comparison the levcles of serum ALT, AST, TBiL, DBiL, gamma GGT and ALP, IL-4. IL-6, IFN gamma, TNFa of patients between two groups, there was no sta tistically significant difference （P〉0.05）;After treatment, serum ALT, AST, TBiL, DBiL, gamma GGT and ALP, TNF-α, IFN- gamma of the treatment group patients were lower, compared with before treatment, IL-4 and IL-6 levels were higher, differences were statistically significant （P〈0. 05） respectively; Show that Thl type eytokine levels drop, Th2 type cytokines levels elevate;After treatment, compared with the control group, the levels of IL-4, IL 6 elevate in treatment group, TNF-a, I FN-gamma levels drop, the difference was statistically significant （P〈0.05）. Conclusion Mechanism that l_Jrsodeoxycholic Acid capsules treat the cholestasis liver disease patients may be related to inhibit from the Thl cells releasing cytokines TNF- α and IFN-gamma and the same time stimulate the Th2 cells releasing cytokines IL-4 and IL-6. So, Ursodeoxycholic Acid capsules may have certain immune regulation in the treatment of cholestasis liver disease.

关 键 词：胆汁淤积性肝瘸 熊去氧胆酸胶囊 白细胞介素-4 白细胞介素-6 Γ-干扰素 肿瘤坏死刚子-α 

分 类 号：R735.7[医药卫生—肿瘤]